119 related articles for article (PubMed ID: 33654787)
1. Capillary Nano-immunoassay for Quantification of Proteins from CD138-purified Myeloma Cells.
Misiewicz-Krzeminska I; Isidro I; Gutiérrez NC
Bio Protoc; 2019 Jun; 9(12):e3267. PubMed ID: 33654787
[TBL] [Abstract][Full Text] [Related]
2. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.
Misiewicz-Krzeminska I; Corchete LA; Rojas EA; Martínez-López J; García-Sanz R; Oriol A; Bladé J; Lahuerta JJ; Miguel JS; Mateos MV; Gutiérrez NC
Haematologica; 2018 May; 103(5):880-889. PubMed ID: 29545347
[TBL] [Abstract][Full Text] [Related]
3. Development of an automated capillary nano-immunoassay-Simple Western assay-to quantify total TDP43 protein in human platelet samples.
Fourier A; Escal J; Bernard E; Lachman I; Perret-Liaudet A; Leblanc P; Quadrio I
Anal Bioanal Chem; 2019 Jan; 411(1):267-275. PubMed ID: 30374726
[TBL] [Abstract][Full Text] [Related]
4. Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
Malherbe JAJ; Fuller KA; Mirzai B; Augustson BM; Erber WN
J Clin Pathol; 2022 Jan; 75(1):50-57. PubMed ID: 33234694
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
6. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
7. Cryopreservation Preserves Cell-Type Composition and Gene Expression Profiles in Bone Marrow Aspirates From Multiple Myeloma Patients.
Chen D; Abu Zaid MI; Reiter JL; Czader M; Wang L; McGuire P; Xuei X; Gao H; Huang K; Abonour R; Walker BA; Liu Y
Front Genet; 2021; 12():663487. PubMed ID: 33968139
[TBL] [Abstract][Full Text] [Related]
8. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
9. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
Beekman C; Janson AA; Baghat A; van Deutekom JC; Datson NA
PLoS One; 2018; 13(4):e0195850. PubMed ID: 29641567
[TBL] [Abstract][Full Text] [Related]
10. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.
Al-Quran SZ; Yang L; Magill JM; Braylan RC; Douglas-Nikitin VK
Hum Pathol; 2007 Dec; 38(12):1779-87. PubMed ID: 17714757
[TBL] [Abstract][Full Text] [Related]
11. Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients.
Rampa C; Tian E; Våtsveen TK; Buene G; Slørdahl TS; Børset M; Waage A; Sundan A
Biomark Res; 2014 Apr; 2(1):8. PubMed ID: 24716444
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
13. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
15. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring.
Liu ZY; Tian MY; Deng L; Wang YS; Xing R; Liu H; Fu R
Hematol Oncol; 2019 Oct; 37(4):401-408. PubMed ID: 31291481
[TBL] [Abstract][Full Text] [Related]
16. CD138
Wu D; Zhang P; Li F; Shen Y; Chen H; Feng Y; He A; Wang F
Aging (Albany NY); 2020 Nov; 12(22):23067-23081. PubMed ID: 33197893
[TBL] [Abstract][Full Text] [Related]
17. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
18. Heavy/light chain assay in the monitoring of multiple myeloma.
Ting HY; Sthaneshwar P; Bee PC; Shanmugam H; Lim M
Pathology; 2019 Aug; 51(5):507-511. PubMed ID: 31253381
[TBL] [Abstract][Full Text] [Related]
19. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
